Use of polyamidoamine dendrimers in brain diseases

Maria Florendo, Alexander Figacz, Bhairavi Srinageshwar, Ajit Sharma, Douglas Swanson, Gary L. Dunbar, Julien Rossignol

Research output: Contribution to journalReview articlepeer-review

49 Scopus citations


Polyamidoamine (PAMAM) dendrimers are one of the smallest and most precise nanomolecules available today, which have promising applications for the treatment of brain diseases. Each aspect of the dendrimer (core, size or generation, size of cavities, and surface functional groups) can be precisely modulated to yield a variety of nanocarriers for delivery of drugs and genes to brain cells in vitro or in vivo. Two of the most important criteria to consider when using PAMAM dendrimers for neuroscience applications is their safety profile and their potential to be prepared in a reproducible manner. Based on these criteria, features of PAMAM dendrimers are described to help the neuroscience researcher to judiciously choose the right type of dendrimer and the appropriate method for loading the drug to form a safe and effective delivery system to the brain.

Original languageEnglish
Article number2238
Issue number9
StatePublished - Sep 3 2018


  • Blood-brain barrier
  • DNA delivery
  • Drug delivery
  • Nanoparticles
  • Neurodegenerative diseases
  • PAMAM dendrimers


Dive into the research topics of 'Use of polyamidoamine dendrimers in brain diseases'. Together they form a unique fingerprint.

Cite this